ELUTIA INC. Investment Update

Hey there! Let's break down what's going on with ELUTIA INC. in a way that makes sense, without all the fancy finance talk. Think of this as me explaining it to you over coffee.

---

1. What happened? Alright, so ELUTIA INC. just announced their early, unofficial financial results for the last three months of 2025 (the fourth quarter). These are called "preliminary results" because they haven't been fully checked and approved by auditors yet. But here's the exciting part: they've actually shared some key numbers and big plans!

Specifically, they reported preliminary net sales of about $3.3 million, which is a nice 16% increase compared to the same time last year. Even better, they completely paid off a $26.9 million loan from SWK Holdings, which significantly strengthens their financial position by reducing interest expenses. They also ended the year with a healthy $36.3 million in cash, plus another $8.0 million held in escrow from a previous sale (the BioEnvelope business), bringing their total available funds to $44.3 million.

Beyond the numbers, Elutia also gave us a peek into their future, focusing on a new product called NXT-41x. This is a next-generation product designed to prevent infections in plastic and reconstructive surgery, especially for breast reconstruction, which is a huge market.

2. When did it happen? This news broke today, January 12, 2026. The company's Chief Financial Officer, Matthew Ferguson, signed off on this report today.

3. Why did it happen? So, why did this all go down? Well, companies regularly share how they're doing financially. This is a standard update to let investors know about their performance for the end of last year. But this time, it's more than just routine numbers; they're also laying out their strategic vision and future product development plans, especially for their new NXT-41x product. It's about showing where they're headed and how they plan to grow.

4. Why does this matter? This isn't just some small update; it's a big deal because these preliminary results now give us an early, concrete peek into how ELUTIA performed financially at the end of 2025.

• Financial Health: The 16% sales increase shows good growth, and paying off that $26.9 million debt is a huge positive, meaning less interest to pay and a stronger balance sheet. Their $44.3 million in cash gives them a solid cushion to fund their future plans.
• Future Growth: The focus on NXT-41x is a major strategic move. This product aims to tackle a big problem – infections in breast reconstruction surgery – in a $1.5 billion market. If successful, this could be a game-changer for the company. They've already had success with a similar product (EluPro, which they sold for $88 million to Boston Scientific), so there's a proven track record for their technology.

Generally, financial results and future plans can significantly impact how investors view the company's health and future, so these details are what everyone was waiting for.

5. Who is affected? When something big like this happens, it touches a lot of people:

• Employees: The company's strengthened financial position and clear strategic direction with NXT-41x could mean more stability and exciting development work ahead.
• Customers (and future patients): While not directly affected by the financial report itself, the development of NXT-41x could eventually lead to better outcomes for patients undergoing breast reconstruction surgery, potentially reducing infection rates.
• Investors (that's us!): This news, with actual numbers and future plans, will definitely make ELUTIA's stock price move. The positive financial news (sales growth, debt repayment, cash) and the promising new product focus could be seen very favorably.
• Competitors: They'll be watching Elutia's new product development closely, especially in the breast reconstruction market, to see how it might impact their own strategies.

6. What happens next? Okay, so what's the immediate future look like?

• Short-term: The market will react now to these specific preliminary numbers and the strategic update. Expect stock price movements as investors digest the sales growth, debt repayment, strong cash position, and the new product focus.
• Mid-term: Keep an eye on the FDA milestones for NXT-41 and NXT-41x. They plan to file for NXT-41 (their novel base matrix) approval in the first half of 2026, with anticipated clearance in the second half of 2026. For the antibiotic-eluting NXT-41x, they expect FDA clearance in the first half of 2027. These regulatory steps are crucial for the product's future.
• Long-term: These preliminary results will eventually be finalized and included in the company's official annual report, which will be audited. We'll be keeping an eye on their next earnings call for more details and the confirmed financial figures.

7. What should investors/traders know? Here's the practical stuff for you:

• Key Takeaways: Elutia is showing good sales growth (16%), has significantly reduced its debt by paying off $26.9 million, and has a strong cash position of $44.3 million. This makes them financially much stronger.
• Future Focus: The company is putting its energy into NXT-41x, a product for breast reconstruction that could address a significant medical need and a large market. The upcoming FDA milestones are important dates to watch.
• Still Preliminary: Remember, these are still preliminary numbers and could change slightly after the full audit. However, they give a very strong indication of the company's performance.
• Do your homework: Now that the numbers are out, you can compare them to what analysts expected. Did they beat expectations? That's often a big driver for stock movement. Also, research the breast reconstruction market and the potential of NXT-41x.
• Consider your own goals: With this new information, you can better assess the impact on your personal investment strategy.
• Volatility is normal: Big news like this, especially with positive financial results and clear future plans, can create a lot of ups and downs. That's just how the market reacts to new information.

---

Hope this helps you get a clearer picture of what's going on with ELUTIA INC.!